1. Minna JD. Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Molecular biology overview. Lung cancer: principles and practice. 1996. 1st ed. Philadelphia: Lippincott-Raven;143–148.
2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002. 20:18 Suppl. 1S–13S.
3. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998. 58:5032–5037.
4. Mao L. Recent advances in the molecular diagnosis of lung cancer. Oncogene. 2002. 21:6960–6969.
Article
5. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010. 2:a001008.
Article
6. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000. 77:81–137.
Article
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000. 408:307–310.
Article
8. Pfeifer GP, Besaratinia A. Mutational spectra of human cancer. Hum Genet. 2009. 125:493–506.
Article
9. Jassem E, Nikliński J, Rosell R, Niklińska W, Jakóbkiewicz J, Monzo M, et al. Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients. Lung Cancer. 2001. 34:Suppl 2. S47–S51.
10. Feng Z, Hu W, Rom WN, Costa M, Tang MS. Chromium(VI) exposure enhances polycyclic aromatic hydrocarbon-DNA binding at the p53 gene in human lung cells. Carcinogenesis. 2003. 24:771–778.
Article
11. Pfeifer GP, Denissenko MF, Oliver M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002. 21:7435–7451.
Article
12. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res. 2001. 61:6350–6355.
13. Lee EB, Jin G, Lee SY, Park JY, Kim MJ, Choi JE, et al. TP53 mutations in Korean patients with non-small cell lung cancer. J Korean Med Sci. 2010. 25:698–705.
Article
14. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene. 1999. 18:211–218.
Article
15. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 2003. 100:8424–8429.
Article
16. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989. 246:491–494.
Article
17. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res. 2005. 11:2502–2509.
Article
18. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 1996. 47:285–301.
Article
19. Horio Y, Takahashi T, Kuroshi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993. 53:1–4.
20. Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, et al. Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra. Am J Pathol. 2000. 157:2133–2141.
Article
22. Hernandez-Boussard TM, Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect. 1998. 106:385–391.
Article
23. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999. 187:8–18.
Article
24. Pfeifer GP, Denissenko MF, Tang M. p53 mutations, benzo[a]pyrene and lung cancer: a reply. Mutagenesis. 1998. 13:537–538.
Article